Health & Life Sciences

NEW YORK; April 4, 2019 – The adoption of a unique combination of the best in science and health technology such as genomics, biomarkers and companion technologies are expected to be the biopharmaceutical industry’s new growth machine, according to new research from Accenture (NYSE: ACN).

NEW YORK and DUBLIN, Ireland; Mar. 5, 2019 – Accenture (NYSE: ACN) has agreed to acquire Enterprise System Partners (ESP), a consulting and manufacturing services provider for the life sciences industry that is headquartered in Cork, Ireland, serving clients around the globe. Upon close, ESP will join Accenture Industry X.0, which helps clients master the digital reinvention of industry, strengthening Accenture’s capabilities to transform manufacturing for pharmaceutical, biotech and medical device clients globally.

SAN FRANCISCO; Jan. 8, 2019 – Ayasdi has been named the Accenture HealthTech Innovation Challenge Innovation Champion, competing with more than 1,100 companies for the title. The competition pairs leading-edge startups with prominent health and life sciences organizations to develop innovative technology solutions that improve the way people access and manage healthcare.

NEW YORK; Dec. 21, 2018 – Using conversational artificial intelligence to improve care management and leveraging patient experiences to incentivize patients in their own health journey are among the innovative solutions being developed by the four North America-based finalists selected for the Accenture HealthTech Innovation Challenge.

PARIS; Dec. 11, 2018 – Pierre Fabre has selected Accenture (NYSE: ACN) to build an intelligent information technology (IT) platform to support and improve the performance of a range of functions — including finance, accounting, procurement, order management and manufacturing — essential to the company’s global operations. The program is part of one of the most significant and strategic transformation initiatives ever undertaken at the French multinational health and beauty care company.

NEW YORK and LAS VEGAS; Nov. 26, 2018 – Accenture (NYSE: ACN) has created an open partner ecosystem designed to help independent software vendors (ISVs) and life sciences companies team more effectively to accelerate drug discovery efforts and, ultimately, improve patient outcomes.

NEW YORK; Sept. 21, 2018 – Accenture (NYSE: ACN) has enhanced the Accenture Intelligent Patient Platform with the addition of Ella and Ethan, two interactive virtual-assistant bots that use artificial intelligence (AI) to constantly learn and make intelligent recommendations for interactions between life sciences companies, patients, health care providers (HCPs) and caregivers. Designed to help improve a patient’s health and overall experience, the bots are part of Accenture’s Salesforce Fullforce Solutions powered by Salesforce Health Cloud and Einstein AI, as well as Amazon’s Alexa.  

NEW YORK; Sept. 17, 2018 – Accenture and Merck, known as MSD outside the United States and Canada, in collaboration with Amazon Web Services (AWS), will launch a cloud-based informatics research platform designed to help organizations in the life sciences industry improve productivity, efficiency and innovation in the early stages of drug development.

NEW YORK; Aug. 21, 2018 – Accenture (NYSE: ACN) is positioned for a third consecutive time as a Leader in the IDC MarketScape vendor assessment, covering strategic consulting across the life sciences research and development (R&D) industry.

NEW YORK; July 30, 2018 – For the third consecutive time, Accenture (NYSE: ACN) is positioned as a Leader in the IDC MarketScape vendor assessment covering IT outsourcing (ITO) across the life sciences research and development (R&D) industry.